期刊
EXPERT REVIEW OF VACCINES
卷 21, 期 7, 页码 957-974出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14760584.2021.1903878
关键词
Dry powder vaccine; IgA; inhalation; MALT; mucosal immunity; pulmonary administration; respiratory viruses; SARS-COV-2; vaccines
类别
资金
- Swiss National Science Foundation [CRSII5_180323]
- Swiss National Science Foundation (SNF) [CRSII5_180323] Funding Source: Swiss National Science Foundation (SNF)
The article discusses the current status and potential advantages of inhaled vaccines against viral pathogens, suggesting the feasibility of developing inhalable dry powder formulations. Inhalable vaccines can increase vaccine stability, facilitate mass vaccination, and provide improved protection through inducing an IgA-mediated mucosal immune response.
Introduction As underlined by the late 2019 outbreak of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), vaccination remains the cornerstone of global health-care. Although vaccines for SARS-CoV-2 are being developed at a record-breaking pace, the majority of those that are licensed or currently registered in clinical trials are formulated as an injectable product, requiring a tightly regulated cold-chain infrastructure, and primarily inducing systemic immune responses. Areas covered Here, we shed light on the status of inhaled vaccines against viral pathogens, providing background to the role of the mucosal immune system and elucidating what factors determine an inhalable vaccine's efficacy. We also discuss whether the development of an inhalable powder vaccine formulation against SARS-CoV-2 could be feasible. The review was conducted using relevant studies from PubMed, Web of Science and Google Scholar. Expert opinion We believe that the scope of vaccine research should be broadened toward inhalable dry powder formulations since dry vaccines bear several advantages. Firstly, their dry state can tremendously increase vaccine stability and shelf-life. Secondly, they can be inhaled using disposable inhalers, omitting the need for trained health-care personnel and, therefore, facilitating mass-vaccination campaigns. Thirdly, inhalable vaccines may provide improved protection since they can induce an IgA-mediated mucosal immune response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据